VITEK 2 AST-草黃桉桿酸鹽（<=0.125 - >=8 µg/mL）
K 號：K260281 · 2026-03-26
廣告
器材摘要
VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) is the device name listed in this FDA 510(k) record. The listed applicant is BIOMERIEUX. It received FDA 510(k) clearance on 2026-03-26 under 510(k) number K260281. The device is classified under product code LON. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.
常見問題
What is the VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)?
VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) is a medical device that received FDA 510(k) clearance on 2026-03-26. The listed applicant is BIOMERIEUX. The 510(k) number is K260281.
When did VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) receive FDA 510(k) clearance?
VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) received FDA 510(k) clearance on 2026-03-26, under 510(k) number K260281.
Who is the listed applicant for VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)?
The FDA 510(k) record lists BIOMERIEUX as the applicant. This does not by itself establish the device manufacturer.
What is the FDA product code for VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)?
The FDA product code for VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) is LON.
相關臨床試驗
相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係，請查閱連結的官方來源。
相關器械（代碼：LON）
相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係，請查閱連結的官方來源。
K260282VITEK 2 AST-引起性青銅色球菌克林達霉素抗藥性bioMerieux, Inc.K251579VITEK 2 AST-革蘭氏陰性細菌頭孢噻呋（=<1-=>32 µg/mL）bioMerieux, Inc.K251713BD Phoenix自動微生物學系統 - GN Eravacycline (0.125-2 µg/mL)Becton, Dickinson and CompanyK250447BD Phoenix™自動微生物學系統 - GN Imipenem-relebactam (0.0625/4 - 16/4 µg/mL)Becton, Dickinson and CompanyK234012VITEK 精簡型 PRObioMerieux, Inc.K250344BD Phoenix™自動微生物學系統Becton, Dickinson and Company
官方來源
在 FDA 資料庫中查看 →資料來源為 FDA Open API。如需最新且權威的資訊，請始終參閱官方記錄。
廣告